A meta-analysis of two Gynecologic Oncology Group (GOG) clinical trials shows a clear long-term survival benefit for intraperitoneal (IP) therapy over intravenous (IV) treatment of ovarian cancer. The results were presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Los Angeles.
A meta-analysis of two Gynecologic Oncology Group (GOG) clinical trials shows a clear long-term survival benefit for intraperitoneal (IP) therapy over intravenous (IV) treatment of ovarian cancer. The results were presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Los Angeles.
The findings, based on data from GOG clinical trials 114 and 172, represented outcomes in 876 women with advanced ovarian cancer. GOG-114 randomized patients with optimally resected stage III ovarian cancer to IV cisplatin/paclitaxel or to IV carboplatin followed by IP cisplatin/paclitaxel. In COG-172, women with resected stage III ovarian cancer were randomized to therapy with IV paclitaxel followed by either IV cisplatin or IP cisplatin and IP paclitaxel.
The new analysis showed a benefit of IP over IV therapy that extended beyond 10 years, with median survival time for both trials at 10.7 years. Median survival was 61.8 months for IP therapy, versus 51.4 months for IV treatment (P=0.048). IP therapy was associated with a 17% decrease in risk of death (adjusted hazard ratio [AHR]=0.83, 85% CI, 0.71-0.97; P=0.02). Younger age, better performance status, non-clear cell/mucinous histology, low-grade histology, and microscopic disease all were predictive of improved survival after IP therapy.
IP therapy’s survival advantage was evident in women with both microscopic (IP vs IV: 65% vs 58%) and gross residual disease (IP vs IV: 44% vs 35%). The 5-year survival rate was 59% in those who completed 5 or 6 cycles of IP therapy, compared to 18% vs 33% with 1 or 2 vs 3 or 4 cycles, respectively (P<0.001). Younger patients and women with microscopic residual disease were more likely to complete 6 cycles.
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Early intrauterine balloon tamponade and severe postpartum hemorrhage risk
November 14th 2023A recent study indicates that early use of intrauterine balloon tamponade does not significantly reduce severe postpartum hemorrhage risk compared to its application after second-line uterotonic treatment failure.
Read More
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More